Stock Analiz

Medpace Holdings, Inc. (MEDP) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026

Summary

Medpace’s revenue went from $422M in fiscal 2016 to $2.5B in fiscal 2025, growth of about 22.0% a year.

Net income in fiscal 2025 was $451M, a net margin of 17.8%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $2.8B and net income $518M.

Free cash flow was $682M in fiscal 2025 and positive in 10 of the 10 years shown.

The diluted share count fell 19% over the period (buybacks).

Revenue, profit and cash flow by year

Revenue
2016: $422M162017: $436M172018: $705M182019: $861M192020: $926M202021: $1.1B212022: $1.5B222023: $1.9B232024: $2.1B242025: $2.5B25$2.5B
Net income
2016: $13M162017: $39M172018: $73M182019: $100M192020: $145M202021: $182M212022: $245M222023: $283M232024: $404M242025: $451M25$451M
Free cash flow
2016: $78M162017: $86M172018: $141M182019: $184M192020: $227M202021: $235M212022: $351M222023: $397M232024: $572M242025: $682M25$682M
EPS (diluted)
2016: $0.37162017: $0.98172018: $1.97182019: $2.67192020: $3.84202021: $4.81212022: $7.28222023: $8.88232024: $12.63242025: $15.2825$15.28

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$2.8B$2.5B$2.1B$1.9B$1.5B$1.1B$926M$861M$705M$436M$422M
Gross profit———————————
Operating income$607M$535M$447M$337M$279M$199M$167M$127M$101M$65M$52M
Net income$518M$451M$404M$283M$245M$182M$145M$100M$73M$39M$13M
EPS (diluted)$18.01$15.28$12.63$8.88$7.28$4.81$3.84$2.67$1.97$0.98$0.37
R&D———————————
Revenue growth—+20.0%+11.8%+29.2%+27.8%+23.4%+7.5%+22.2%+61.6%+3.5%+17.4%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$723M$713M$609M$433M$388M$263M$259M$202M$157M$97M$92M
Capital spending-$55M-$31M-$37M-$37M-$37M-$28M-$31M-$18M-$16M-$12M-$14M
Free cash flow$668M$682M$572M$397M$351M$235M$227M$184M$141M$86M$78M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks$295M$917M$170M$144M$848M$62M$98M$0$0$156M$0
Stock-based pay$22M$35M$26M$21M$21M$14M$14M$21M$6M$4M$10M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$497M$669M$245M$28M$461M$278M$132M$23M$26M$37M
Debt—$137M$150M$164M$208M$147M$131M$56M$80M$223M$165M
Equity—$459M$826M$559M$386M$953M$806M$726M$599M$509M$611M
Total assets—$2.0B$2.1B$1.7B$1.4B$1.7B$1.4B$1.1B$968M$951M$979M
Shares (diluted)28M30M32M32M34M38M38M38M37M40M36M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin———————————
Operating margin21.4%21.1%21.2%17.9%19.1%17.4%18.0%14.8%14.3%14.9%12.4%
Net margin18.2%17.8%19.2%15.0%16.8%15.9%15.7%11.7%10.4%9.0%3.2%
FCF margin23.5%27.0%27.1%21.0%24.1%20.6%24.6%21.4%20.0%19.6%18.6%
ROIC—74.7%38.9%39.2%40.7%16.3%15.4%13.1%11.6%6.1%4.1%
ROE—98.3%49.0%50.6%63.5%19.1%18.0%13.8%12.2%7.7%2.2%

Frequently asked questions

What is Medpace’s annual revenue?

$2.5B in fiscal 2025 and $2.8B over the twelve months to September 30, 2026.

How much profit does Medpace make?

Net income was $451M in fiscal 2025 (net margin 17.8%).

Is Medpace’s revenue growing?

Yes: revenue rose 20.0% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.